Last reviewed · How we verify
NCT04768179: IVCOM
Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients
Phase 2, PHASE3 trial testing 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1) in Covid19 in 490 participants. Status unknown.
30 June 2021
Quick facts
| Lead sponsor | Makerere University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 490 |
| Start date | 19 February 2021 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 September 2021 |
Drugs / interventions tested
- 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1) — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Makerere University
Who can join
Adults 18 to 64, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19, caused by the novel Severe Acute Respiratory Syndrome Corona Virus 2 (SARSCoV-2), has become a global pandemic. Fortunately, most of the COVID-19 cases confirmed are categorized as mild for whom home- based symptomatic management with monitoring of clinical deterioration is recommended. Despite providing symptomatic management, a therapeutic drug that would limit the course of infection is greatly needed to stop COVID-19 disease progression. Considering the current SARS-CoV-2 epidemiology and the legitimate rash towards appropriate therapies, our study seeks to evaluate the safety and efficacy of low dose aspirin and ivermectin combination therapy in COVID-19 patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ivermectin for preventing and treating COVID-19.
Popp M, Stegemann M, Metzendorf MI, Gould S, et al · · 2021 · cited 102× · PMID 34318930 · DOI 10.1002/14651858.cd015017.pub2 -
The roles of lipids in SARS-CoV-2 viral replication and the host immune response.
Theken KN, Tang SY, Sengupta S, FitzGerald GA. · · 2021 · cited 59× · PMID 34599996 · DOI 10.1016/j.jlr.2021.100129 -
Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.
Chen P, Wu M, He Y, Jiang B, et al · · 2023 · cited 50× · PMID 37286535 · DOI 10.1038/s41392-023-01510-8 -
Ivermectin for preventing and treating COVID-19.
Popp M, Reis S, Schießer S, Hausinger RI, et al · · 2022 · cited 30× · PMID 35726131 · DOI 10.1002/14651858.cd015017.pub3 -
Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19.
Ricciotti E, Laudanski K, FitzGerald GA. · · 2021 · cited 11× · PMID 34303107 · DOI 10.1016/j.jbior.2021.100818 -
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.
Kumar S, Basu M, Ghosh P, Pal U, et al · · 2023 · cited 7× · PMID 37334160 · DOI 10.1016/j.gendis.2022.12.019 -
Antiplatelet agents for the treatment of adults with COVID-19.
Fischer AL, Messer S, Riera R, Martimbianco ALC, et al · · 2023 · cited 5× · PMID 37489818 · DOI 10.1002/14651858.cd015078 -
Lipid metabolism, viral infection, and antiviral immunity: a new host-pathogen interface.
Yang LJ, Tang M, Yang L. · · 2026 · PMID 41868152 · DOI 10.3389/fcimb.2026.1765502
Verify or expand the search:
- PubMed search for NCT04768179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Makerere University trials
Trials by the same sponsor.
- NCT07407868 — Call for Life Sepsis · NA · not yet recruiting
- NCT06975670 — Enhancing Comprehension of Consent in Patients With Psychotic Disorders · NA · not yet recruiting
- NCT06139198 — Self-management Intervention for Reducing Epilepsy Burden Among Ugandans With Epilepsy. · NA · recruiting
- NCT06791928 — Peer Delivered HIV/Syphilis Self-Testing With Assisted Partner Notification Services · Phase 2 · enrolling by invitation
- NCT06563440 — Development and Evaluation of an Information Management System and Communication System for Population-wide Point-of-car · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04768179 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Makerere University
- Last refreshed: 24 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04768179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing